Latvian Institute of Organic Synthesis

Stealth Biotherapeutics Inc.

Pavels Arsenjans

Jelena Vasiljeva

Ivars Kalvins

Guozhu Zheng

Dennis Keefe

Ilona Domracheva

Irina Shestakova

Ilona Domraceva

Pavels Dimitrijevs

Iveta Kanepe-Lapsa

Anita Gulbe

Valerjans Kauss

The present invention relates to a novel selenophenochromene hydroxamic acids as angiogenesis inhibitors, as well as methods of their manufacturing and use in different pharmaceutical compositions for the treatment or prevention of various diseases and disorders by administration of such substances.

Selenophenochromene hydroxamic acids, preparation and use as angiogenesis inhibitors

The disclosure provides therapeutic compositions (i.e., therapeutic agents) and methods of preventing or treating Friedreich's ataxia in a mammalian subject, reducing risk factors, signs and/or symptoms associated with Friedreich's ataxia (e.g., Complex I deficiency), and/or reducing the likelihood or severity of Friedreich's ataxia. The disclosure further provides novel intermediates for the production of said therapeutic compositions and related reduced versions of said therapeutic compositions, which reduce forms may also be used as therapeutic agents (or prodrugs of the therapeutic agent(s)).

Compositions and methods for the prevention and/or treatment of mitochondrial disease, including Friedreich's ataxia

The present invention relates to a novel cancer metastasis preventing and curing selenopheno[h]chromene derivatives, as well as methods of their manufacturing and use in different pharmaceutical compositions for the treatment and/or prevention of primary cancer and its metastasis by administration of such substances. 

Antimetastatic 2H-selenopheno[3,2-h]chromenes, synthesis thereof, and methods of using same agents

Growing community of inventors

Riga, Latvia

Pavels Arsenjans